… Hope R Lapointe , Hope R Lapointe … While COVID-19 vaccines offer hope to end the
pandemic [4–7], real-world assessments have revealed weaker vaccine-induced immune …

Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain
incompletely characterized. We measured circulating antibodies against the SARS-CoV-2 spike …

… Hope R Lapointe , Hope R Lapointe … We thank the phlebotomists and laboratory staff at St
Paul's Hospital, the BC Centre for Excellence in HIV/AIDS, the Hope to Health Research and …

Background: Longer-term humoral responses to two-dose COVID-19 vaccines remain
incompletely characterized in people living with HIV (PLWH), as do initial responses to a third …

Efforts to cure HIV have focused on reactivating latent proviruses to enable elimination by
CD8 + cytotoxic T-cells. Clinical studies of latency reversing agents (LRA) in antiretroviral …

… j,q,r ; Margolese, Shari e ; Mandarino, Enrico e ; Samarani, Suzanne a ; Vulesevic,
Branka e,s ; Lebouché, Bertrand a,b,t,u ; Angel, Jonathan B. g,s ; Routy, Jean-Pierre a,b,v ; …

Background Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19)
vaccines remain incompletely characterized in people living with human …

Background: Limited data exist regarding longer term antibody responses following three-dose
coronavirus disease 2019 (COVID-19) vaccination, and the impact of a first SARS-CoV-2 …

Objective: Limited data exist regarding the immune benefits of fourth COVID-19 vaccine doses
in people with HIV (PWH) receiving antiretroviral therapy (ART), particularly now that most …

SARS-CoV-2 Omicron infections are common among individuals who are vaccinated or
have recovered from prior variant infection, but few reports have immunologically assessed …